胰高血糖素样肽-1受体激动剂治疗糖尿病肾病研究进展  

Research progress on glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy

作　　者：朱轶 桂定坤[2] 汪年松 ZHU Yi;GUI Dingkun;WANG Niansong(Macao University of Science and Technology,Macao 999078,China;Department of Nephrology,Shanghai Jiao Tong University School of Medicine,Shanghai Sixth People's Hospital,Shanghai 200233,China)

机构地区：[1]澳门科技大学,中国澳门999078 [2]上海交通大学附属上海市第六人民医院肾脏内科,上海200233

出　　处：《世界临床药物》2023年第1期1-7,共7页World Clinical Drug

基　　金：国家自然基金面上项目(81770741、81870504、82270761);上海市领军人才(058)资助。

摘　　要：胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是一种新型降糖药物,作用靶点多样,可改善氧化应激、抗炎、减轻晚期糖基化终末产物损害、调节肾素-血管紧张素-醛固酮系统、改善内皮功能以及减轻肾纤维化等,并发挥肾脏保护作用,在临床上被应用于糖尿病肾病(diabetic nephropathy,DN)的治疗。现就近年来发表的关于GLP-1RA治疗DN的临床应用和作用机制的文献进行综述,为临床提供参考。Glucagon-like peptide-1 receptor agonist(GLP-1RA)is a novel hypoglycemic agent with a variety of targets.It is widely used in the treatment of diabetic nephropathy(DN),which is characterized by improving oxidative stress and anti-inflammatory effects,alleviating damage of advanced glycosylation end-products,regulating renin-angiotensinaldosterone system,improving endothelial function,alleviating renal fibrosis,and playing a protective role in the kidney.This paper reviewed the literatures published in recent years on the clinical application and mechanism of GLP-1RA in the treatment of DN,so as to provide reference for clinical practice.

关 键 词：胰高血糖素样肽-1受体激动剂 糖尿病肾病 氧化应激 

分 类 号：R587.1[医药卫生—内分泌] R587.2[医药卫生—内科学]